University of Glasgow
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Private
- Established
- 1451-01-07
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.gla.ac.uk
Weight Loss Injections Show Promising Anti-Cancer Effects Beyond Weight Reduction
• Research presented at the European Congress on Obesity suggests weight loss injections may reduce obesity-related cancer risk by nearly 50%, potentially through anti-inflammatory mechanisms beyond simple weight reduction.
• Scientists from the University of Manchester are designing a large-scale clinical trial involving tens of thousands of patients to further investigate GLP-1 agonists as cancer prevention tools.
• Experts believe these findings could herald a "new dawn" in preventative cancer medicine, potentially benefiting even non-obese individuals with high cancer risk factors.
Tirzepatide Shows Favorable Muscle Composition Changes in Type 2 Diabetes Patients, SURPASS-3 Trial Analysis Reveals
• Post-hoc analysis of Lilly's SURPASS-3 trial reveals tirzepatide treatment in type 2 diabetes patients leads to muscle volume changes proportional to weight loss, with greater than expected reductions in muscle fat infiltration.
• The study, conducted by AMRA Medical in collaboration with researchers from University of Glasgow, University Hospitals Cleveland, and Eli Lilly, provides crucial data on muscle-related changes during pharmacologically induced weight reduction.
• Professor Naveed Sattar notes these findings address concerns about muscle effects of newer weight loss drugs, suggesting tirzepatide may actually improve muscle efficiency through reduced fat infiltration.
EnteroBiotix Reports Promising Phase 2a Results for Novel Microbiome Therapy in IBS-C
• EBX-102-02, a full-spectrum microbiome product, demonstrated clinically meaningful improvements over placebo in patients with moderate to severe IBS-C, showing benefits in symptom severity, stool consistency, and abdominal pain.
• The therapy was well-tolerated with primarily mild, self-limiting gastrointestinal side effects, and metagenomic sequencing confirmed significant shifts in intestinal microbiota composition that persisted during follow-up.
• Based on these positive results, EnteroBiotix plans to accelerate development with a larger Phase 2b trial later this year, potentially addressing a critical unmet need in IBS treatment.
Novel Radiotherapy Approach Helps Rectal Cancer Patients Avoid Permanent Stoma Surgery
• A groundbreaking clinical trial demonstrates that contact X-ray brachytherapy combined with chemo-radiotherapy increases rectum preservation rates from 56% to 79% in rectal cancer patients.
• The innovative treatment approach allows doctors to target tumors directly while protecting healthy tissue, significantly improving patients' quality of life by avoiding permanent stoma surgery.
• Five-year global trial involving 141 patients proves successful, with one participant achieving complete cancer remission through three rounds of brachytherapy followed by standard treatment.
Vivistim VNS Therapy Shows Promising Real-World Outcomes in Chronic Stroke Recovery
• Real-world data from 25 chronic stroke patients demonstrates significant improvement in upper extremity function with Vivistim paired VNS therapy, showing mean FMA-UE score increase of 9.53 points.
• The FDA-approved breakthrough device proves effective even in patients averaging 3.6 years post-stroke, with successful outcomes in 22 of 25 patients completing the six-week protocol.
• Microtransponder's Vivistim therapy has gained significant adoption, now utilized by 20% of Joint Commission Comprehensive Stroke Centers and 50% of top neuro and spine programs.
Tenax Therapeutics Appoints Gillian Andor as VP of Clinical Operations to Bolster Phase 3 Program
• Tenax Therapeutics has appointed Gillian Andor as Vice President of Clinical Operations to support its Phase 3 program for oral levosimendan (TNX-103).
• Ms. Andor brings over 20 years of experience in clinical operations, including NDA submissions and approvals, to accelerate the Phase 3 LEVEL study.
• Her expertise will be crucial as Tenax Therapeutics advances oral levosimendan for pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
• The appointment signifies Tenax's commitment to strengthening its clinical development capabilities as it prepares for potential global regulatory filings.
AstraZeneca's AZD1390 to Be Evaluated in GBM AGILE Trial for Glioblastoma
• AstraZeneca's AZD1390 will be assessed in the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) trial to treat newly diagnosed glioblastoma patients.
• The global adaptive platform trial aims to accelerate the identification and confirmation of effective glioblastoma therapies through its unique design.
• AZD1390, a brain-penetrant ATM kinase inhibitor, impedes ATM-dependent signaling and DNA repair, potentially enhancing glioblastoma treatment.
• Recruitment for the AZD1390 arm of the trial is anticipated to commence in the second quarter of next year, with data potentially supporting regulatory submissions.
AstraZeneca's AZD1390 to be Evaluated in GBM AGILE Trial for Glioblastoma
• AstraZeneca's AZD1390 will be evaluated in the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) trial, a global adaptive platform.
• The trial, designed with response adaptive randomization and a Phase II/III structure, aims to accelerate the identification of effective glioblastoma therapies.
• AZD1390 arm will focus on newly diagnosed glioblastoma patients, with recruitment anticipated to commence in the second quarter of next year.
• GBM AGILE, operating under a master protocol, allows concurrent evaluation of multiple treatments against a common control arm.
AZD1390 to be Evaluated in GBM AGILE Trial for Newly Diagnosed Glioblastoma
• AstraZeneca's AZD1390, a brain-penetrant ATM kinase inhibitor, will be evaluated in the GBM AGILE trial for newly diagnosed glioblastoma patients.
• GBM AGILE is an adaptive platform trial designed to expedite the identification of effective therapies for glioblastoma, an aggressive brain cancer.
• AZD1390 has shown encouraging preliminary efficacy in recurrent glioblastoma and potential as a radiosensitizer in earlier studies.
• Patient recruitment for the AZD1390 arm of the GBM AGILE trial is expected to commence by Q2 2025.
Genetically Engineered Salmonella Shows Promise in Bowel Cancer Treatment
• Researchers have genetically engineered *Salmonella* to target and combat bowel cancer cells, potentially turning a disease-causing bacterium into a therapeutic agent.
• The engineered *Salmonella* strains elicited an immune response in mice with bowel cancer, allowing their immune systems to remain functional during treatment.
• The study identified a key protein responsible for T cell dysfunction during *Salmonella* treatment, offering a genetic target to enhance the therapy's effectiveness.
• Further research is needed to refine the bacterial treatment and fully understand the impact of *Salmonella* on cancer, paving the way for potential clinical applications.
AZD1390, an ATM Kinase Inhibitor, to Be Evaluated in GBM AGILE Trial for Glioblastoma
• AstraZeneca's AZD1390, a novel ATM kinase inhibitor, will be evaluated in the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) trial.
• AZD1390 will be assessed as a treatment for newly diagnosed glioblastoma, with patient recruitment slated to commence in early 2025.
• GBM AGILE is an international adaptive platform trial designed to evaluate multiple therapies simultaneously against a shared control arm.
• AZD1390 has demonstrated a manageable safety profile and preliminary efficacy in combination with radiotherapy in a phase I trial for glioblastoma.
AZD1390 to be Evaluated in GBM AGILE Trial for Newly Diagnosed Glioblastoma
• AstraZeneca's AZD1390, a brain-penetrant ATM kinase inhibitor, will be evaluated in the GBM AGILE trial for newly diagnosed glioblastoma patients.
• The GBM AGILE trial, an adaptive platform trial, aims to identify effective therapies for glioblastoma, the most aggressive form of primary brain cancer.
• AZD1390 has shown encouraging preliminary efficacy in recurrent glioblastoma patients and potential as a radiosensitizer in earlier studies.
• Patient recruitment for the AZD1390 arm of the GBM AGILE trial is expected to commence in Q2 2025.
AZD1390 to be Evaluated in GBM AGILE Trial for Glioblastoma
• AstraZeneca's AZD1390, a brain-penetrant ATM kinase inhibitor, will be evaluated in the GBM AGILE trial for newly diagnosed glioblastoma patients.
• GBM AGILE is an adaptive platform trial designed to expedite the identification of effective therapies for glioblastoma, an aggressive brain cancer.
• AZD1390 has shown preliminary efficacy and a manageable safety profile in combination with radiotherapy in a Phase I trial for glioblastoma patients.
• Recruitment for the AZD1390 arm of the GBM AGILE trial is expected to begin in Q2 2025, with the goal of improving outcomes for glioblastoma patients.
EnteroBiotix's EBX-102 Shows Promise in Phase 1b Liver Cirrhosis Study
• EnteroBiotix announced positive Phase 1b results for EBX-102 in liver cirrhosis, demonstrating potential as a novel microbial therapy.
• The study showed EBX-102 was well-tolerated, with mainly mild gastrointestinal adverse events and no serious treatment-emergent issues.
• Participants receiving EBX-102 exhibited significant shifts in stool bacterial composition and metabolites, suggesting enhanced ammonia excretion.
• Improvements in mental health scores were observed in treatment groups, indicating potential gut-brain-axis effects and supporting further development.
Tirzepatide's Benefits and Risks Re-Evaluated After UK Death
• Tirzepatide's safety and benefits are under scrutiny following a reported death in the UK, prompting a re-evaluation of its risk profile.
• Clinical trial data involving approximately 10,000 participants suggest tirzepatide has acceptable safety with benefits like weight loss and diabetes prevention.
• Experts emphasize the need for vigilance and comprehensive data analysis, cautioning against drawing conclusions from single case reports.
• Tirzepatide's common side effects include nausea, diarrhea, vomiting, and constipation, while uncommon issues such as acute pancreatitis can occur.
UK Government Invests in AI and MedTech to Revolutionize Cancer Detection and Treatment
• The UK government is investing in new technologies, including AI, to improve cancer detection and treatment, aiming to boost the life sciences industry.
• New partnerships between the NHS, pharmaceutical companies, and universities will trial innovative approaches for faster cancer diagnoses and better treatments.
• Funding of £118 million will establish five new health technology hubs across the UK, fostering collaboration between academia and the private sector.
• The investments also focus on personalized treatments and utilizing patient data to train AI models for quicker and more accurate cancer diagnoses.
Resolution Therapeutics Secures $83 Million to Advance Macrophage Therapy for End-Stage Liver Disease
• Resolution Therapeutics has secured $83 million in Series B financing to advance RTX001, a novel macrophage therapy, into clinical trials for end-stage liver disease.
• The EMERALD Phase I/II trial, evaluating RTX001, is set to begin in the UK and Spain in Q4 2024, marking a significant step for this potential first-in-class treatment.
• The funding will also support the expansion of Resolution's macrophage therapy platform into other inflammatory and fibrotic conditions, including graft-vs-host disease.
• Paul Sekhri, a seasoned life sciences executive, has been appointed as Chair of the Board of Directors, bringing extensive experience to guide Resolution's growth.
Torasemide Shows Promise in Genetically-Targeted Hypertension Treatment
• A new study reveals that torasemide, a loop diuretic, significantly reduces blood pressure in hypertension patients with a specific UMOD gene variant.
• Patients with two copies of the UMOD gene variation experienced a 5% reduction in average blood pressure after 16 weeks of torasemide treatment.
• The research suggests personalized treatment based on genetic profiles could improve hypertension management, especially for those with uncontrolled blood pressure.
• Larger trials are needed to confirm torasemide's efficacy as a tool against uncontrolled hypertension, potentially benefiting millions.
Amycretin Shows Promising Weight Loss Results in Phase 1 Trial
• A Phase 1 study of oral amycretin, a novel amylin and GLP-1 receptor co-agonist, demonstrates statistically significant weight loss compared to placebo over 12 weeks.
• The study reports that amycretin was associated with mild to moderate gastrointestinal side effects, but was generally well-tolerated.
• Experts emphasize that larger trials are needed to assess long-term efficacy, safety, and impact on disease outcomes compared to existing injectable treatments.
• Oral medications like amycretin could increase treatment options and potentially lower costs, improving access for individuals with obesity.
Finerenone Extends Event-Free Survival in Heart Failure Patients, Study Finds
• Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, is projected to extend event-free survival by up to 3 years in heart failure patients.
• The benefits were observed across a broad age range (50-80 years) and in patients already treated with SGLT2 inhibitors, a guideline-recommended therapy.
• The FINEARTS-HF trial data supports finerenone's role in modifying longitudinal risks of clinical events, aiding clinical decision-making for heart failure.
• The study highlights the potential of finerenone to improve outcomes in heart failure with mildly reduced or preserved ejection fraction.
© Copyright 2025. All Rights Reserved by MedPath